Design of the PEDS-C trial: Pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection

Clinical Trials

Volumn 4, Issue 6, 2007, Pages 661-673

  Murray, Karen F ^a,h   Rodrigue, James R ^b   González Peralta, Regino P ^c   Shepherd, John ^d   Barton, Bruce A ^e   Robuck, Patricia R ^f   Schwarz, Kathleen B ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; CHILD; CHILD GROWTH; CHRONIC HEPATITIS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FINANCIAL MANAGEMENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FUNDING; HEPATITIS C; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; PEDIATRICS; PRESCHOOL CHILD; PROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; PEDIATRICS; PLACEBOS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES;

EID: 40949152504     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507085445     Document Type: Article

References (55)

1. Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28(5): 1416-23.
2. Rosenthal P. Chronic hepatitis C viral infection in childhood: to treat or not to treat with interferon-that is the question. J Pediatr Gastroenterol Nutr 1997; 23: 363-64.
3. Fried M, Hoofnagle J. Therapy of hepatitis C. Semin Liver Dis 1995; 15(1): 82-91.
4. Pensati P, Iorio R, Botta S, et al. Low virological response to interferon in children with chronic hepatitis C. J Hepatol 1999; 31: 604-11.
5. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of Interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34(1): 52-58.
6. Willhite CC, Ferm VH. Potentiation of ribavirin-induced teratogenesis by natural purines. Exp Mol Pathol 1978; 28: 196-201.
7. Ferm VH, Willhite CC, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratol 1978; 17: 93-102.
8. Kochar DM, Penner JD, Knudsen TB. Embryotoxic, teratogenic, and metabolic effects of Ribavirin in mice. Toxicol Appl Pharmacol 1980; 52: 99-112.
9. Agnish, MD. An oral gavage study for effects of RO 20-9963 (Ribavirin) on fertility and early embryonic development to implantation in Sprague dawley rats (Covance Study No 6131-316, Roche Study No 07392) RR 1003508.
10. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
11. Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-a therapy on growth of children. J Viral Hepatitis 2001; 8: 139-47.
12. Gottrand F, Michaud L, Guimber D, et al. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155: 1031-34.
13. Briend A, Garenne M, Maire B, et al. Nutritional status, age, and survival: the muscle mass hypothesis. Eur J Clin Nutr 1989; 43: 715-26.
14. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone of in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England J Med 1998; 339(21): 1493-99.
15. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 1998; 339(21): 1485-92.
16. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 1426-32.
17. Manns MP, McHutchison JC, Gordon SC, et al. Pegilated interferon lafa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
18. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-82.
19. Malek-Ahmadi P. Mood disorders associated with interferon treatment: theoretical and practical considerations. Ann Pharmacother 2001; 35: 489-95.
20. Musselman D, Lawson D, Gumnick J, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344: 961-6.
21. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
22. Bagheri H, Fouladi A, Barange K, et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004; 24: 1546-53.
23. Raison C, Borisov A, Broadwell S, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
24. Kraus M, Schafer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005; 11: 1769-74.
25. González-Peralta RP, Kelly DA, Haber B, et al. Nterferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005.
26. Corporation S. Medical Economics 2002; 3153-57.
27. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy: The Consensus Interferon Study Group. Hepatology 1999; 29: 264-70.
28. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-9.
29. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol. 2001; 32: 413-7.
30. Spiegel, BMR, Younossi, ZM, Hays, RD et al. Impact of hepatitis C on health-related quality of life: a systematic review and quantitative assessment. 2005; 41: 790-800.
31. Posthouwer D, Plug I, van der Bom JG, et al. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005; 90: 846-50.
32. Schwarz KB, Mohan P, Narkewicz M, et al. The Safety, Efficacy and Pharmacokinetics of Peginterferon Alpha-2a (40KD) in Children with Chronic Hepatitis C. Gastroenterology 2003; 124: 4(Suppl 1): A700.
33. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41(5): 1013-1018.
34. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy. Annals of Internal Medicine 1996; 125(8): 634-9.
35. Herrine SK, Rossi S, Navarro VJ. Management of patients with chronic hepatitis C infection. Clin Exp Med 2006; 6: 20-26.
36. Reynolds WM, Anderson G, Bartell N. Measuring depression in children: A multimethod assessment investigation. J Abnorm Child Psychol 1985; 13: 513-26.
37. Association, AP. Quick reference to the Diagnostic Criteria from DSM-IV-TR. 2000.
38. Lan K, Demets D. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
39. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
40. Pampallona S, Tsiatis A, Kim K. Interim monitoring of group sequential trials using spending functions for Type I and Type II error probabilities. Drug Information J 2001; 35: 1113-21.
41. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10.
42. Division of AIDS Toxicity Table for Grading Severity of Pediatric (>3 months of Age) Adverse Experiences, www.niaid.nih.gov/dmid/clinresearch/ DMIDpedtox.doc
43. PACTG Adherence Questionnaire, www.fstrf.org/qol/peds/pedadhere.html
44. United States Department of Health, Education and Welfare. Ten-state nutrition survey in the United States 1968-1970. 1972, Centers for Disease Control, Atlanta.
45. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibrations results. J Bone Mineral Res 1995; 9(10): 1503-14.
46. Interferon Plus Ribavirin Approved for First-Line Treatment of Hepatitis C, in Antiviral Agents Bulletin. 1998; 354.
47. Landgraf JM, Abetz L, Ware JE. The CHQ user's manual. The Health Institute, New England Medical Center, Boston, 1996.
48. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function., in Psychological Assessment Resources. 2000, Odessa.
49. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms & profiles. University of Vermont, Research Center for Children, Youth, and Families, Burlington, 2001.
50. Achenbach TM, Rescorla LA. Manual for ASEBA Adult Forms and Profiles. Univ. of Vermont, Research Center for Children, Youth, and Families, Burlington, 2003.
51. Kazak AE, Rourke MT, Crump TA. In Roberts MC. (Ed). Families and other systems in pediatric psychology. , 2003, pp. 159-175.
52. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston, The Health Institute, 1993.
53. Hammad TA, Oaughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 3329.
54. Wietzke-Braun P, Meier V, Neubauer-Saile K, et al. Treatment of genotype 2 and 3 chronic hepatitis C virus infected patients. World J Gastroenterol 2005; 11(39): 6188-92.
55. Ellis KJ, Shypailo RJ, Pratt JA, Pond WG. Accuracy of dual-energy x-ray absorptiometry for body-composition measurements in children. Am J Clin Nutr 1994; 60(5): 660-65.